

# Index

## A

- Acute rhinosinusitis, 58
- AERD. *See* Aspirin-exacerbated respiratory disease (AERD)
- Airway eosinophils, 182
- Airway inflammation, 4, 7, 9, 11, 13, 18
- Airway smooth muscle (ASM), 142
- Alair® Bronchial Thermoplasty System, 142
- Allergen immunotherapy (AIT), 283
- Allergic asthma, 117, 174
  - allergen-specific immunotherapy
    - efficacy, 170
    - role of, 171
    - SCIT with anti-IgE therapy, 171
    - subcutaneous injections, 170
    - sublingual immunotherapy, 170
    - trials, 170
  - biologic therapies, 172
    - IL-4/IL-13, 173
    - interleukin IL-5, 173
    - omalizumab, 172–173
  - definition, 156
  - diagnosis
    - exposure to sensitizing aerollergens, 159, 160
    - skin testing, 160
    - testing for specific IgE, 160
  - environmental challenges, 161
  - immunology, 157
  - indoor allergens exposure, 161
    - and asthma exacerbation, 162
    - cockroach allergy, 165–166
    - furry pets, 162–164
    - house dust mites, 164–165
    - IgE sensitization, 161
    - mold, 167–168
    - multifactorial environmental interventions, 168–170
    - rodents, 167
  - pharmacologic therapy, 171
    - inhaled corticosteroids, 171
    - oral steroids, 172
  - prevalence, 156
  - vs. non-allergic asthma, 156
- Allergic bronchopulmonary aspergillosis (ABPA), 15, 186
- Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines, 268
- Allergic rhinitis and sinusitis, 29–30
  - childhood severe asthma, 268
  - cross-sectional study, 57
  - evaluation, 57
  - exacerbation rates and symptom scores, 56
  - management
    - biological agents, 59
    - for acute rhinosinusitis, 58
    - for chronic rhinosinusitis, 59
    - immunotherapy, 58
    - intranasal steroid and intranasal antihistamine sprays, 57
    - leukotriene receptor antagonist, 58
- NHLBI Severe Asthma Research Program (SARP)-3 study, 56
- SIIVA and LODO cohort study, 56
- Amoxicillin-clavulanate, 58
- Anaphylaxis, 171
- Anti-IL-5 therapy, 137–139
- Anti-IL-6 therapy, 320
- Apnea hypopnea index (AHI), 61

- Aspirin-exacerbated respiratory disease (AERD)  
 electronic medical record, 60  
 evaluation, 60  
 management, 60  
 prevalence, 60
- Asthma, 117, 181  
 and chronic cough, 29–30  
 annual economic burden, 314  
 biologic drugs, 133–135  
 anti-IL-5 therapy, 137–138  
 benralizumab, 140  
 dupilumab, 140–141  
 FDA approved, 133  
 IL-33 receptor antibody, 141  
 mepolizumab, 137–139  
 omalizumab, 136–137  
 reslizumab, 139  
 tezepelumab, 133, 141  
 definition, 2  
 diagnosis  
 accurate, 12  
 criteria for, 12, 13  
 differential diagnosis, 27–29  
 financial impact, 4, 108  
 heterogeneous disorder, 108  
 immune targeted therapies, 17–18  
 in children, differential diagnosis, 266, 267  
 incorrect diagnosis, 26  
 management  
 adherence to asthma medications, 316  
 anti-IgE/anti-IL5 biologics, 315  
 bronchial thermoplasty, 315  
 control-based, 15–16  
 health care disparities, 316  
 ICS with LABA, 315  
 medications and therapeutic options, 16–17  
 mortality rates, 3  
 new model of, 9  
 non-type 2, 316–317  
 omics  
 GWAS studies, 317  
 multi-omics databases, 318  
 systems biology approach, 318  
 pathophysiology, 9  
 immune responses, 9–11  
 structural defects, 11–12  
 prevalence, 2, 25, 108  
 international, 2  
 obesity, 229  
 United States, 3  
 problem with over diagnosis, 26–27  
 risk factors  
 air pollution, 7  
 environmental exposure, 4–5  
 indoor allergen exposure, 5  
 microbiome exposures, 6  
 obesity, 7–8  
 occupational exposures, 8  
 phenotypes, 5  
 psychosocial stressors, 8  
 respiratory viruses, 6  
 sex hormones, 8  
 smoking, 7  
 severity and control assessment  
 airflow limitation, 12  
 exacerbation, 14  
 for uncontrolled asthma, 15  
 GINA guidelines, 12  
 stepwise medications, 14  
 symptom control, 14  
 symptoms, 26  
 tracheal stenosis, 33  
 work-up for asthma mimics, 27, 28
- Asthma Control Questionnaire (ACQ) scores, 14, 143, 182, 183, 212, 251
- Asthma Control Test (ACT), 14, 182, 183, 212
- Asthma Intervention Research (AIR) Trial, 143
- Asthma Intervention Research 2 (AIR2) Trial, 143
- Asthma mimics, 300  
 differential diagnosis, 27–29  
 excessive dynamic airway collapse, 34  
 foreign body, 34  
 management, 34–35  
 tracheobronchomalacia, 34  
 vocal cord dysfunction (*see* Vocal cord dysfunction (VCD))
- Asthma Quality of Life Questionnaire (AQLQ) scores, 143, 212
- B**
- Baker's asthma, 76
- Beclomethasone, 17, 94, 97, 256, 258
- Benralizumab, 18, 129, 133, 136, 139, 140, 173, 184, 193, 196, 197, 283, 320
- Biomarkers, 112, 144  
 associated with non-type 2 inflammation, 131–133  
 associated with T2 inflammation, 127  
 FeNO, 131  
 IgE, 130  
 in severe asthma, 124–127  
 targeted asthma therapies, 125  
 uses, 124
- Bronchial hyperresponsiveness (BHR), 279
- Bronchial thermoplasty (BT), 142

- AIR1 and RISA trial, 143
- AIR2 Trial, 143
- animal trial, 143
- influences airway smooth muscle, 142
- mechanism of action, 144
- multi-detector computed tomography, 144
- non-allergic/non-inflammatory asthma, 144
- non-eosinophilic asthma, 217
- patient selection, 144
- Post-FDA Approval Clinical Trial Evaluating
  - Bronchial Thermoplasty in Severe Persistent Asthma study, 144
- probe, 142
- radio frequency energy, 142
- randomized human trials, 143
- Bronchiectasis, 27, 182, 185, 280, 300
- Bronchoprovocation testing, 26, 27, 66, 67, 279, 300, 304
- BT. *See* Bronchial thermoplasty (BT)
  
- C**
- Cardiopulmonary exercise testing (CPET), 35
- Centers for Disease Control and Prevention (CDC), 314
- Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2), 197
- Childhood Asthma Management Program (CAMP), 8, 114, 281
- Childhood severe asthma
  - biologic therapies, 282, 283
  - determinants, 272
    - exposure to indoor airborne irritants, 275–276
    - exposures with indoor allergens, 274, 275
    - genetic susceptibility, 273
    - outdoor environment, 276
    - respiratory viruses, 274
    - school environment, 276
- vs.* difficult-to-control asthma, 266
  - allergic rhinitis, 268
  - asthma masqueraders, 266
  - GERD, 269
  - obesity, 268
  - poor medication adherence, 269–270
  - SDB, 269
- evaluation, 278
  - biomarkers and phenotyping, 279
  - bronchoscopy, 280
  - imaging studies, 280
  - pulmonary function testing, 278–279
  - questionnaires, 277
  - scoring indices, 280
- management
  - exacerbation prevention, 281–284
  - treating exacerbations, 284
- ongoing research areas, 284, 285
- phenotypes
  - APIC study, 270
  - asthma severity, clinical factors, 272
  - cluster analysis, 271
  - difficult-to-control asthma,
    - characteristics and endotype of, 272
    - NHLBI-sponsoredSARP III, 270
  - prevalence and burden of, 266
- Chlorofluorocarbons (CFCs), 92
- Chronic care management (CCM)
  - models, 48–49
- Chronic cough, 29–30
- Chronic oral corticosteroids (OCS), 17
- Chronic rhinosinusitis, 15, 57, 59, 117
- Chronic rhinosinusitis with nasal polyps (CRSwNP), 59
- Chronic rhinosinusitis without nasal polyps (CRSsNP), 59
- Clostridium botulinum toxin, 68
- Cluster analysis, 112
  - SARP adult, 113
    - classification, 112
    - inflammatory clustering, 114
    - phenotypes, 114
    - SARPediatric cluster analysis, 114–115
    - unbiased, 303
- Cockroach allergy, 5, 6, 58, 162, 165–166, 168, 169, 246, 274
- Composite Asthma Severity Index (CASI), 280
- C-reactive protein (CRP), 320
  
- D**
- Diet, 62, 208, 232, 236, 319–320
- Difficult-to-treat asthma, 108
  - comorbidities associated with, 56
    - AERD, 60–61
    - allergic rhinitis and sinusitis (*see* Allergic rhinitis and sinusitis)
    - GERD (*see* Gastroesophageal reflux disease (GERD))
    - OSA syndrome (*see* Obstructive sleep apnea (OSA) syndrome)
    - VCD (*see* Vocal cord dysfunction (VCD))
  - definition, 55
  - evaluation and management, 56–58
  - vs.* sever, 298–299

Disability adjusted life year (DALY), 3  
 Dose Ranging Efficacy And Safety With  
 Mepolizumab in Severe Asthma  
 (DREAM) trial, 138, 190  
 Doxycycline, 58, 59  
 Dry powder inhalers (DPIs), 17, 92–94, 100,  
 270  
 Dupilumab, 18, 59, 60, 117, 129, 131, 133,  
 140–141, 173, 196, 197, 259, 283  
 Dysanapsis, 230

## E

EA. *See* Eosinophilic asthma  
 E-cigarettes, 7, 276  
 Effectiveness of Low Dose Theophylline as  
 Add-on Treatment in Asthma  
 (LODO) trial, 56  
 Electronic monitoring devices, 46  
 Emotional stress, 301  
 Environmental tobacco smoke (ETS), 275  
 Eosinophilic asthma (EA), 117, 198, 315  
   biological therapy, 189  
   biomarkers to gauge treatment  
     effectiveness, 318  
   diagnosis  
     blood eosinophilia, 184  
     FeNO, 185  
     periostin, 186  
     serum immunoglobulin E, 186  
     sputum eosinophils, 184  
     sputum vs. blood eosinophils, 185  
 inflammatory endotype, 182  
 management, 183  
   corticosteroids, 188–189  
   FeNO measurement, 188  
   LABA, 189  
   LAMA, 189  
   macrolides, 189  
   monoclonal antibodies (*see* Monoclonal  
     antibodies (mAbs))  
   montelukast and roflumilast, 189  
   sputum-based approach, 188  
 monitoring and follow-up, 198  
 non-pulmonary etiology, 186  
 prevalence, 182  
 pulmonary etiology, 186  
 Eosinophilic bronchitis, 27, 29, 182  
 Eosinophilic inflammation, 18, 112, 127–130,  
 158, 182, 185, 186, 188–190, 197,  
 198, 212  
 Epworth Sleepiness Scale score, 56, 62  
 European Community Respiratory Health  
 Survey (ECRHS), 2

European Network for Understanding  
 Mechanisms of Severe Asthma  
 (ENFUMOSA), 8  
 Excessive dynamic airway collapse (EDAC), 34  
 Exercise induced bronchospasm (EIB), 66  
 Exercise-induced laryngeal obstruction  
 (EILO), 66, 68  
 Expression quantitative trait loci (eQTL)  
 methods, 318

## F

Fevipirant, 197  
 Fine-particle fraction (FPF), 93  
 Formoterol, , 100, 250, 257, 96  
 Fraction of exhaled nitric oxide (FeNO), 98,  
 99, 114, 117, 131, 183, 185, 188,  
 189, 208, 249, 250, 278, 279, 282,  
 316, 318  
 Fractional excretion of nitric oxide (FENO), 17

## G

Gasdermin B/orosomucoid like 3  
 (GSDMB-ORMDL3), 4  
 Gastroesophageal reflux disease (GERD)  
   and asthma, 63  
   childhood severe asthma, 269  
   evaluation, 64  
   management  
     adjunctive therapy, 64  
     bedtime H2 receptor antagonist, 64  
     invasive treatments, 65  
     Nissen and Toupet fundoplication, 65  
     PPIs therapy, 64  
   medications, 63  
   prevalence, 63  
   pulmonary function tests, 63  
 Genome-wide association studies  
 (GWAS), 4, 317, 318  
 Geometric standard deviation (GSD), 93  
 GERD. *See* Gastroesophageal reflux disease  
 (GERD)  
 Global Initiative for Asthma (GINA)  
   asthma  
     definition, 2  
     diagnostic criteria for, 13  
     guidelines, 16, 98, 161, 171, 277, 278  
     step 4-5 therapy, 136  
 Gross national product (GNP), 3

## H

HDMs. *See* House dust mites (HDMs)

- Heterogeneity in severe asthma, 110  
 biased approach  
   age of asthma onset and atopy, 111  
   airway inflammatory in sputum, 112  
   chronic airflow obstruction, 111  
   unbiased approaches (*see* Cluster analysis)
- HFAs. *See* Hydrofluoroalkanes (HFAs)
- High-risk asthma clinic  
 access to advances therapies, 303  
 assist with phenotyping, 303  
 diagnostic uncertainties, 300  
 education and training program, 303  
 impact of, 299  
 long-term use of OCS, 302  
 management, 301  
   comorbidities, 301  
   concept and business plan, 304  
   consulting specialists, 305  
   core competencies, 305  
   core team structure, 304  
   criteria for patient discharge, 306  
   facility, 304  
   inhaler technique, 302  
   poor medication adherence, 301  
   referral pathways, 306  
   structured approach, 306  
   triggers, 301  
 multidisciplinary patient-centered team  
   structure, 305  
 optimizing patient's self-management  
   skills, 302  
 purpose of, 299  
 systematic evaluation, 307
- House dust mites (HDMs), 15, 156, 159, 160,  
 162, 164–166, 168, 169, 171
- Human pregnancy summary safety data,  
 253–255
- Human rhinovirus (HRV), 6
- Hydrofluoroalkanes (HFAs), 17, 92, 102
- Hypopharyngeal multi-channel intraluminal  
 impedance (HMI), 64
- I**
- ICS. *See* Inhaled corticosteroid (ICS)
- Immunoglobulin E (IgE), 10, 76, 130, 157,  
 160, 164, 172, 186, 190, 218, 237,  
 259, 280, 318
- Immunomodulatory biologic therapies,  
 282–284
- Immunotherapy  
 allergen-specific (*see* Allergic asthma)  
 severe allergic rhinitis, 58  
 subcutaneous, 170, 171  
 sublingual, 171, 253
- Inducible laryngeal obstruction (ILO). *See*  
 Vocal cord dysfunction (VCD)
- Infectious Disease Society of America (IDSA)  
 guidelines, 58
- Inhalant allergen immunotherapy (AIT), 283
- Inhaled bronchodilator, 257, 279
- Inhaled corticosteroid (ICS), 3, 9, 55, 183  
 add-on therapy to, 98  
 adherence, 40, 42, 46, 48, 270  
 development of, 16  
 doses, 144, 233  
   comparison in asthma, 17  
   high, 10, 14–16, 97, 101, 130, 138,  
   142, 188–190, 196, 299  
   increasing *vs.* LABA addition,  
   97, low, 14  
   reduced, 99  
 exacerbation prevention, 281–282  
 fixed dose *vs.* ICS/LABA, 100–101  
 generic options for, 41  
 with LABA, 95–96, 281, 315  
 nonadherence, 40  
 for non-eosinophilic asthma, 212  
 during pregnancy, 253, 255–256, 258  
 in preventing exacerbations and achieving  
   control, 281–282  
 and roflumilast, 215  
 safety and adverse effects, 102  
 side effects, 94–95  
 and theophylline, 215
- Inhaled medications  
 biomarkers, 98–99
- ICS (*see* Inhaled corticosteroid (ICS))
- inhaler  
 delivery and efficacy data, 93–94  
 dry powder inhalers, 92  
 particle size, 93  
 pressurized metered dose, 92  
 propellant, 92
- LABA safety, 95–96
- stepping down asthma therapy  
 fixed dosage ICS/LABA therapy, 99  
 guidelines, 99  
 variable dosing ICS/LABA, 100, 101
- stepping up asthma therapy  
 ICS *vs.* LABA, 97  
 LAMA, 98  
 traditional asthma therapies, 101
- Inhaled short-acting beta-agonists  
 (SABA), 256
- Innate lymphoid cells (ILC's), 10, 157  
 type 2 (ILC2), 127, 141, 158–159, 185, 232
- Inner-City Asthma Study (ICAS), 6

International Study of Asthma and Allergy in Children (ISAAC), 2  
 Internet-based monitoring system (IBS), 319  
 Interleukin (IL-6), 132, 210, 214, 320  
 Irritant-induced asthma, 77, 80, 83, 85

## L

LABA. *See* Long-acting beta-agonists (LABAs)  
 LAMA. *See* Long-acting muscarinic antagonists (LAMA)  
 Laryngeal dysfunction, 182  
 Laryngopharyngeal reflux (LPR), 64  
 Lebrikizumab, 141, 197, 320  
 Long-acting beta-agonists (LABAs), 183, 189, 219, 281, 299, 315  
   addition of, 98, 281  
   fixed vs. variable dosing, 100–101  
   inhaled, 257  
   long-term use of, 211  
   non-eosinophilic asthma, 218  
   for obesity-driven asthma, 211  
   during pregnancy, 257  
   safety, 95–96  
   stepping down fixed-dosage, 99–100  
 Long-acting bronchodilators including beta agonists (LABA), 142  
 Long-acting muscarinic antagonists (LAMA), 98, 142, 183, 189, 211, 212, 216, 219, 234, 299

## M

Macrolides, 189, 282  
 Marijuana smoking, 276  
 Material Safety Data Sheets (MSDSs), 80  
 Maternal asthma, 248, 259  
 Maternal smoking, 232  
 Mechanisms of the Development of ALLergy (MeDALL) study, 268  
 Medication adherence  
   assessment  
     advantages and limitations, 44  
     electronic medication monitoring, 44  
     lower tech approach, 44  
     MARS measurement, 43  
     objective data, 44  
     permission-giving approach, 45  
     practical approach, 45  
     self-report data, 43–44  
   interventions, 48  
     clinician-based approaches, 47

    health systems-based approaches, 48–49  
     patient-based approaches, 45–46  
     pharmacy-based approaches, 47  
 Medication Adherence Rating Scale (MARS), 43, 44  
 Medication nonadherence, 40  
   advanced age, 42–43  
   cognitive impairment, 41  
   cost, 40–41  
   depression, 42  
   health literacy, 41  
   inaccurate beliefs, 42  
   intentional concerns, 42  
   necessity beliefs, 42  
   ‘no symptoms-no asthma’ belief, 41  
 Mepolizumab, 18, 137–139, 173, 190–196, 283  
 Metered dose inhaler (MDI) devices, 40, 41  
 Mild asthma, 14, 99, 108, 109, 171, 247, 280  
 Mixed granulocytic asthma, 209, 210  
 Moderate asthma, 14, 108, 109, 190, 256, 258  
 Monoclonal antibodies (mAbs)  
   benralizumab, 140, 196  
   dupilumab, 140–141, 196  
   lebrikizumab, 197  
   mepolizumab, 137–139, 190  
   omalizumab, 136–137, 190  
   reslizumab, 139, 196  
   therapeutic approach, 197  
   tralokinumab, 197  
   trials evaluation, 190–195  
 Monodisperse inhalers, 93  
 Montelukast, 58, 189, 233, 254, 258  
 Multidisciplinary Approach to Management of Maternal Asthma (MAMMA), 251  
 Multidisciplinary patient-centered team, 305

## N

NEA. *See* Non-eosinophilic asthma  
 Neutrophil predominant asthma, 209, 212, 215  
 Neutrophilic asthma, 65, 132, 209  
 Non-eosinophilic asthma (NEA), 315  
   biologic agents  
     anti-TSLP, 216  
     IL-17 receptor blockers, 216  
     TNF- $\alpha$ , 216  
   characteristics, 209  
   conventional asthma therapy  
     bronchoconstriction, 211  
     control airway inflammation, 211  
     inhaled corticosteroids, 212

- long acting anti-muscarinics, 212
    - randomized control trials, 211
  - CXCR2 antagonists, 215
  - definition, 208
  - vs. eosinophilic asthma, 207–208
  - mixed inflammatory granulocyte asthma, 209–210
  - neutrophil predominant asthma, 209
  - non-pharmacologic management
    - bronchial thermoplasty, 217
    - weight loss, 217–218
  - obesity-associated, 211
  - off-label medications
    - macrolide antibiotics, 213
    - phosphodiesterase, 215
    - PPAR- $\gamma$  agonist, 214
    - statins, 214
  - paucigranulocytic asthma, 210–211
  - phenotypes
    - ACO, 317
    - biomarkers, 316
  - practical therapeutic approach, 218, 219
- O**
- OASYS-2 computer program
    - (OASYS Research Group, Midland Thoracic Society; Birmingham, UK), 83
  - Obesity and asthma, 7
    - co-morbidities association
      - depression, 234
      - gastroesophageal reflux, 235
      - obstructive sleep apnea, 235
    - drug therapy, 233
      - anti-cholinergics, 234
      - beta agonists, 234
      - biologics agents, 234
      - in children, 233
      - inhaled corticosteroids, 233
      - leukotriene modifiers, 233
    - epidemiology, 229
    - in children, 268
    - management
      - bariatric surgery, 237
      - lifestyle interventions, 236
    - neutrophil predominant asthma, 209
    - phenotype of NEA, 211
    - physiology, 230
    - risk factors, 231
      - environmental factors, 232
      - genetic factors, 232
      - immune abnormalities, 232
      - increased oxidative diet, 232
      - increased oxidative stress, 232
      - metabolic factors, 231
      - vaccination and susceptibility to infection, 234
  - Obstructive sleep apnea (OSA) syndrome
    - characteristics, 61
    - evaluation, 62
    - in children, 61
    - incidence, 61
    - management, 62–63
    - mechanical factors, 61
    - prevalence, 61
    - women with asthma, 62
  - Occupational asthma, 76
    - allergic asthma, 161
    - diagnosis of
      - immunologic tests, 84
      - non-specific airway responsiveness tests, 83
      - specific inhalation challenge, 81
      - spirometry recordings, 81
      - high intensity of exposure, 80
      - high-molecular weight asthmagens, 76
      - irritant-induced asthma, 77–78
      - low-molecular weight asthmagens, 76
      - management
        - work modification, 85
        - worker's compensation claim, 86
      - medical history, 79
      - neutrophil predominant asthma, 209
      - sensitizer-induced asthma, 76
      - symptoms, 80
      - vs. work-exacerbation asthma, 80
  - Omalizumab (anti-IgE), 17, 59, 60, 130, 133, 145, 190, 191, 282
    - allergic asthma, 172–173
    - development program for, 173
    - effect on rhinovirus infection, 274
    - during pregnancy, 249, 254, 259
    - severe asthmatics, 137
    - weight-based dosing, 234
  - Oral corticosteroid (OCS), 183
    - early administration, 284
    - chronic, 17, 55
    - long-term exposure, 302–303
    - non-eosinophilic asthmatics, 315
    - pediatric severe asthma, 108
    - during pregnancy, 259
    - for severe persistent asthma, 253
  - OSA. *See* Obstructive sleep apnea (OSA) syndrome
  - Oxidative stress, 8, 232

**P**

- Paradoxical vocal fold motion (PVFM). *See*  
Vocal cord dysfunction (VCD)
- Patent ductus arteriosus (PDA), 33
- Paucigranulocytic asthma, 210–211
- Peak expiratory flow measurements, 83
- Periostin, 124, 130–131, 186, 197, 208
- Peroxisome proliferator-activated receptor- $\gamma$   
(PPAR- $\gamma$ ) agonists, 214
- Phosphodiesterase (PDE) inhibitors, 215
- Pittsburgh Vocal Cord Index, 33
- pMDIs. *See* Pressurized metered dose (pMDIs)
- Precision Interventions for Severe and/or  
Exacerbation Prone Asthma  
(PrecISE), 316
- Pregnancy and asthma  
complications, 247  
course of, 245  
epidemiology, 244–245  
FeNO-guided treatment, 250  
level of treatment, 249  
non-pharmacological management  
asthma education, 251  
clinical trials, 252  
common colds, 252  
influenza vaccination, 252  
nonadherence medications, 251  
obesity, 251  
psychological state, 250  
smoking and airway  
hyperresponsiveness, 251  
upper respiratory infection/sinusitis,  
252  
viral infections, 252
- offspring outcomes, 247–248
- pharmacologic therapy  
classification, 252  
cromolyn and theophylline, 258  
inhaled corticosteroids, 255  
inhaled short-acting beta-agonists, 256  
leukotriene modifiers, 257  
long-acting beta-agonists, 257  
omalizumab, 259  
oral corticosteroids, 258–259  
other medications, 259  
safety data on medication, 253–255
- prevalence, 244
- pulmonary changes in, 246–247
- severity classification, 249
- smoking e-cigarettes, 7
- Pressurized metered dose (pMDIs), 92  
breath-actuated, 93  
chlorofluorocarbons, 92  
hydrofluoroalkanes, 92

- Preventative Omalizumab or Step-up Therapy  
for Severe Fall Exacerbations  
(PROSE) study, 274
- Pulmonary function testing (PFT), 271

**Q**

- Quantitative sputum cytometry, 183

**R**

- Reactive Airways Dysfunction Syndrome  
(RADs), 77, 78
- Reflux theory, 63
- Repeated upper airway obstruction, 61
- Research in Asthma (RISA) Trial, 143
- Reslizumab, 18, 139, 173, 192, 196
- Respiratory syncytial virus (RSV), 6, 274
- Rhinosinusitis, 35  
acute, 58  
chronic, 15, 57, 59, 117  
topical therapies, 35
- Roflumilast, 188, 189, 215

**S**

- SABA. *See* Short-acting beta-agonists (SABA)
- Safety of Inactivated Influenza Vaccine in  
Asthma in Adults and Children  
(SIIVA) trial, 56
- Salmeterol Multicenter Asthma Research Trial  
(SMART), 96
- SARP. *See* Severe Asthma Research Program  
(SARP)
- Scintigraphy, 94
- Seasonal Asthma Exacerbation Index  
(SAEI), 280
- Self-management behaviors, 40, 49
- Severe asthma, 298  
biomarkers, 124–127, 183  
bronchial thermoplasty  
AIR1 and RISA trial, 143  
AIR2 Trial, 143  
animal trial, 143  
influences airway smooth  
muscle, 142  
mechanism of action, 144  
multi-detector computed  
tomography, 144  
non-allergic/non-inflammatory  
asthma, 144  
patient selection, 144  
Post-FDA Approval Clinical Trial  
Evaluating Bronchial Thermoplasty



- in Severe Persistent Asthma study, 143
    - radio frequency energy, 142
    - randomized human trials, 143
  - definition, 108, 182, 298
  - evaluation, 182
  - heterogeneity in (*see* Heterogeneity in severe asthma)
  - high resource utilization, 298
  - in adults, 109–110
  - in children (*see* Childhood severe asthma)
  - vs.* difficult to treat asthma, 298
  - laryngeal dysfunction, 182
  - pediatric, 108–109
  - phenotypes, 117
    - allergic asthma, 117
    - eosinophilic asthma, 117
  - obesity, prevalence of, 230
  - quantitative sputum cytometry, 183
  - specialized high-risk clinic (*see* High-risk asthma clinic)
  - T-helper 2 immunologic disease, 298
  - treatment strategy, 299
  - Severe Asthma Research Program (SARP), 8, 109, 115, 318
  - Short-acting beta-agonists (SABA), 100, 101, 143, 189, 219
    - high usage, 15
    - non-eosinophilic asthma, 218
    - during pregnancy, 256
  - Single nucleotide polymorphisms, 4
  - Sinusitis, 29
    - and allergic rhinitis (*see* Allergic rhinitis and sinusitis)
    - during pregnancy, 252
    - recurrent, 110
  - Skin prick testing (SPT), 84, 130, 160, 161
  - Sleep-disordered breathing (SBD), 268, 306
    - childhood severe asthma, 269
    - impact, 61
  - Smoking
    - vs.* air-way hyperresponsiveness, 251
    - cessation, 64, 259
    - marijuana, 276
    - maternal, 232
    - neutrophil predominant asthma, 209
    - parental, 232
    - passive, 168
    - second-hand cigarette smoke exposure, 7
  - Snoring, 61
  - Soft mist inhalers, 93, 102
  - Speech therapy, 35, 68
  - Spirometry, 12, 26, 27, 30, 31, 81, 86, 278, 279, 300
  - Sputum inflammatory, 127, 128, 132
  - Statins, 214
  - Subcutaneous immunotherapy (SCIT), 170
- T**
- T helper 2 (Th2) cytokine gene expression, 10
  - Telemedicine-based interventions, 46
  - Tezepelumab, 133, 141, 145, 197, 216
  - TH2 cells, 157–159, 170, 197
  - Theophylline, 16, 215, 253, 255, 258
  - Thymic stromal lymphopoietin (TSLP), 133, 197, 216
  - Tiotropium, 98, 101, 212, 259
  - Tracheobronchomalacia (TBM), 34, 35, 182
  - Tralokinumab, 141, 197, 320
  - Transthoracic echocardiography, 35
  - TSLP. *See* Thymic stromal lymphopoietin (TSLP)
  - Type 2 cytokine antagonists, 10
- U**
- Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED), 318
  - Uncontrolled asthma, 15, 321
    - health disparities, 315
    - heterogeneity and therapeutic approach, 314
    - impact of, 314
    - management
      - anti-IL-6, 320
      - clinic-based telemedicine, 319
      - diet, 319, 320
      - digital hand-held smart devices, 319
      - educational videos and online communities, 319
      - exacerbations prevention, 318
      - inhaled medications, 320
      - mobile apps, 319
      - Mobile apps, 319
      - unmet needs, 319
      - patient compliance, 314
      - poor patient-physician communication, 315
  - Urban Environment and Childhood Asthma (URECA), 6
- V**
- Vaccines and Medications in Pregnancy Surveillance System (VAMPSS), 259
  - Vocal cord dysfunction (VCD), 15, 66
    - accurated diagnosis, 32–33

- and asthma, coexistence of, 32, 66, 67
  - association with asthma mimics, 33
  - definition, 30
  - diagnosis of, 30–32
  - evaluation
    - bronchoprovocation testing, 67
    - dysfunctional breathing, 68
    - impulse oscillometry, 67
    - laryngoscopy, 67
    - patient history, 67
    - pulmonary function tests, 67
  - management, 68
  - misdiagnosed as asthma, 32
  - prevalence, 30, 66
  - retrospective analysis, 30
  - spirometry findings, 30, 31
  - symptoms, 30, 66
- W**
- Wheezing, 26, 34, 108
    - childhood, 109
    - recurrent, 284
    - respiratory viral infections, 6
    - tracheal stenosis, 34
  - Work-exacerbated asthma, 76
    - vs. occupational asthma, 80
    - management, 85
    - morbidity, 76
    - pre-existing asthma patient, 78
    - responsible agents, 78
    - serial peak flow measurements, 83
    - variety of occupations, 78
  - Work-related asthma
    - algorithm, 81
    - case study, 86–87
    - diagnosis, 79
    - allergy skin prick testing, 84
    - atopy and prior allergic disease, 80
    - bronchial hyperresponsiveness
      - measurements, 83
    - exposure history, 80
    - immunoassays, 84
    - non-specific airway responsiveness
      - tests, 83
    - OASYS-2 computer program, 83
    - specific inhalational challenges, 84
    - spirometry, 81
    - sputum eosinophil counts, 84
    - work-relatedness symptoms, 79–80
  - health-care provider, 79
  - management, 76
    - disadvantage, 85
    - dust masks, 85
    - guidelines, 84
    - low level exposure to agent, 85
    - pharmacotherapy, 84
    - respirators, 85
    - work modification, 85
  - morbidity, 76
  - occupational asthma, 76
    - causes of, 77
    - high-molecular weight
      - asthmagens, 76
    - irritant-induced asthma, 77–78
    - low-molecular weight asthmagens, 76
    - peak expiratory flow data
      - interpretation, 82–83
    - sensitizer-induced asthma, 76
  - work-exacerbated asthma, 76
    - pre-existing asthma patient, 78
    - responsible agents, 78
    - in worker's compensation
      - population, 78